Dyskusja nad zastosowaniem przeciwnaczyniowej terapii podtrzymujacej u chorych na rozsianego raka jelita grubego – opis przypadku

Abstract

Author(s): Krzysztof Adamowicz, Marzena Welnicka-Jaskiewicz

Colorectal cancer is the second most common cause of cancer deaths worldwide. Although progress in the development of new drugs over the last two decades have expanded treatment options for this disease, many significant problems relating to their optimization remains to be solved. Recent advances in molecular characteristics of colorectal cancer are building the foundations for further improvement of existing drugs and the development of new targeted therapies. Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor. The results of many studies and meta-analysis showing the efficacy of bevacizumab in the first and second line treatment are inconclusive because of the variety of subgroups of patients in studies. Furthermore, still do not have any marker response to treatment with inhibitors of the anti-VEGF agents. The results of studies using bevacizumab maintenance therapy is promising, but still ambiguous.

Share this article